BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

RVMD upcoming catalysts

Revolution Medicines, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 1 readout(s) and 1 FDA event(s). Subscribe to RVMD (.ics).

Drugs: Gemcitabine, nab-paclitaxel, Irinotecan, leucovorin, Oxaliplatin

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-08-26FDA approvalapprovedREVOLUTION MEDICINES RVMDRASONQUEApproved 2026-08-26: RASONQUE (NDA220910 ORIG1)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-06 est.P3Revolution Medicines, Inc. RVMDNCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinomaactive not recruiting500

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.